title: Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP(8-37).
abstract: The anorectic effect of IP injection of amylin (1 microgram/kg) was abolished by simultaneous IP injection of the amylin receptor antagonist calcitonin gene-related peptide-(8-37) [CGRP(8-37), 10 micrograms/kg]. The IP injection of pancreatic glucagon (400 micrograms/kg) at dark onset also reduced food intake in 24-h food-deprived rats, and this effect was also totally blocked by coadministration of CGRP(8-37) (10 micrograms/kg). In another feeding paradigm with glucagon (540 micrograms/kg IP 3 h into the light phase in 3 h-prefed rats), however, the anorectic effect of glucagon was not significantly antagonized by CGRP(8-37). The anorectic effect of cholecystokinin (CCK) (0.25 microgram/kg) and bombesin (BBS) (2 micrograms/kg) was partly neutralized by CGRP(8-37). In contrast, the anorectic effect of vasopressin (VP) (2.5 micrograms/kg) was not influenced by CGRP(8-37). As glucagon has been shown previously to increase the secretion of amylin, we conclude that the anorectic effect of peripherally administered glucagon is mediated by the release of amylin, at least under certain conditions. This may also be true for CCK and BBS, as these peptides are insulinotropic and may therefore be presumed to increase amylin release.
authors.affiliation: Institute of Veterinary Physiology, University of Zuerich, Switzerland.
authors.forename: T A
authors.initials: TA
authors.lastname: Lutz
authors.forename: E
authors.initials: E
authors.lastname: Del Prete
authors.forename: M M
authors.initials: MM
authors.lastname: Szabady
authors.forename: E
authors.initials: E
authors.lastname: Scharrer
mesh_terms: D000682:Amyloid / Q000378:metabolism; D000818:Animals; D000855:Anorexia / Q000139:chemically induced* / Q000517:prevention & control; D001839:Bombesin / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology*; D005934:Glucagon / Q000494:pharmacology*; D006801:Humans; D058228:Islet Amyloid Polypeptide; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D058287:Receptors, Islet Amyloid Polypeptide; D018000:Receptors, Peptide / Q000037:antagonists & inhibitors; D014667:Vasopressins / Q000494:pharmacology
chemical_list: D000682:Amyloid; D058228:Islet Amyloid Polypeptide; D010446:Peptide Fragments; D058287:Receptors, Islet Amyloid Polypeptide; D018000:Receptors, Peptide; D014667:Vasopressins; C058636:calcitonin gene-related peptide (8-37); D005934:Glucagon; D002766:Cholecystokinin; D015740:Calcitonin Gene-Related Peptide; D001839:Bombesin